Neurocrine (NASDAQ:NBIX): Deutsche Bank lowered its price target for Neurocrine to $18 from $25 after the company’s Phase II study in tardive dyskinesia missed the primary endpoint. Deutsche still sees many opportunities for upside in 2014, including phase III Elagolix results in endometriosis, and the firm keeps a Buy rating on the stock.
The sellers who were buying on momentum & off the new high list have to be cleaned out, which will take a few. Egolix alone is worth the price of the stock so that those who have not been involved should consider NBIX as a tremendous rewards-to-risk looking out the next 6-9 months. Beyond that the stock has a real chance at doubling+.